Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

  • Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M4i0d2Z2dmO2aX;uJGF{e2G7 NFfBc28xNjFvM{Cg{txO M37sXVQ5KGh? M2iyUYlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt NV35UGVwOjZ3MUOxO|I>
H460 MVHGeY5kfGmxbjDBd5NigQ>? MoPRNE4yNTNyIN88US=> NWLqeYI2PDhiaB?= MkCxbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> Ml7mNlY2OTNzN{K=
HKESC-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\vNlDDqM7:TR?= M1fJPVQ5yqCqwrC= M2T2R5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NYrVNoM1OjZ2N{S2PVM>
CaES-17 NXLvU2F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyNOKh|ryP MkTTOFjDqGkEoB?= NUjKcpp6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi NYTSeVFrOjZ2N{S2PVM>
HKESC-2 MXHBdI9xfG:|aYOgRZN{[Xl? NEXsT4UzOMLizszN NHXr[3c1QMLiaNMg MYjy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz Mn\rNlY1PzR4OUO=
CaES-17 NGLQSotCeG:ydH;zbZMhSXO|YYm= M3PvclIxyqEQvF2= NULKSZp7PDkEoHlCpC=> M1LKZZJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> M1yyVFI3PDd2Nkmz
A549 NVL2XGQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD6[oc2NTF4MDFOwG0> NU\mPIxXPDkEoHlCpC=> MmC0SG1UVw>? M2LIbmlEPTB;MU[zMlQh|ryP MX[yOlQ3PDZ2Mx?=
HCC827 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe1MVE3OCEQvF2= NVHjfGJxPDkEoHlCpC=> MorCSG1UVw>? NFT2VGVKSzVyPU[5MlIh|ryP MXiyOlQ3PDZ2Mx?=
A549 MlzuRZBweHSxc3nzJGF{e2G7 NFPWfW05OCEEtV2= NIPBXnA1QMLiaNMg NGqxeFVFVVOR MYLpcoR2[2W|IHHwc5B1d3Orcx?= NHLK[XgzPjR4NE[0Ny=>
HCC827 M322fGFxd3C2b4Ppd{BCe3OjeR?= MX:4NEDDvU1? NHWwd2w1QMLiaNMg NX3GOph{TE2VTx?= MmS2bY5lfWOnczDhdI9xfG:|aYO= NHjT[lIzPjR4NE[0Ny=>
SGC-7901/DDP M2DnSGZ2dmO2aX;uJGF{e2G7 NI\4SWYyOMLiwsXN MYGyOEBp M2XFSYlvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MX[yOlQxPzZ3Mx?=
SGC-7901  NET2W5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TtclI1yqCqwrC= NGXkZYxKSzVyPUGxOU4xQCEQvF2= NFrM[YQzPjRyN{[1Ny=>
SGC-7901/DDP NY\1N2FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Le3V5OjUEoHlCpC=> MYDJR|UxRTN3LkS1JO69VQ>? NWrsRVV1OjZ2MEe2OVM>
SGC-7901/DDP MnLaRZBweHSxc3nzJGF{e2G7 M{LtZlExyqEEtV2= NGD3cW0zPCCq MmjXbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> NYnNUXluOjZ2MEe2OVM>
SGC-7901/DDP MYPGeY5kfGmxbjDBd5NigQ>? NV\De4hoOTEEoNM1US=> NGTqZ4czPCCq MmXObY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? NHnG[WwzPjRyN{[1Ny=>
SGC-7901/DDP M4fZPWZ2dmO2aX;uJGF{e2G7 MkfoNVDDqML3TR?= MUmyOEBp MWLjZZV{\XNiYTDtZZJs\WRiZHXjdoVie2ViaX6geIhmKGyndnXsJI9nKEKlbD2yJJBzd3SnaX6= MXSyOlQxPzZ3Mx?=
H357 NVHBNnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUG3MlUwOTBizszN NXTnUZJyPDhiaB?= NUjmRWJxTE2VTx?= MlzFbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> M4rmXVI3ODB7OEe0
TAF Mn7ZSpVv[3Srb36gRZN{[Xl? M{LDXFExyqEEtV2= NHSxUo04KGR? MYHh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? M1;0cVI2QTh5MUK3
TAF M2PBUWZ2dmO2aX;uJGF{e2G7 NVjwUndXOTEEoNM1US=> MWOzNE0yOjBibXnu NFnve5pxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> MmDZNlU6QDdzMke=
TAF NULWfY5LTnWwY4Tpc44hSXO|YYm= MWKxNOKhyrWP MYS0PEBp Mo\TbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M4e0RVI2QTh5MUK3
PANC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PJS|IxNzZyL{GwNEDPxE1? MlqzNlQwPDhxN{KgbC=> M3rDR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MVOyOVk4OzB4Mh?=
PANC-1 MmLUSpVv[3Srb36gRZN{[Xl? NHnqPWczOC94MD:xNFAh|ryP M1XCc|I1KGh? MmeyZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MVKyOVk4OzB4Mh?=
HeLa  NIr5WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvPc4xCOjEEoN88UeKh NXLkNm1MOjUEoHi= Mkfx[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MV[yOVc4ODR{Mx?=
SACC-83 NWHVfVM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PwNFIxyqEQvF5CpC=> NFzoRWgzPMLiaB?= NWjYOFhy\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NXfncGFjOjV5N{C0NlM>
HeLa  NU\JR4MySXCxcITvd4l{KEG|c3H5 MofYNlDDqM7:TdMg M1zHWlI1yqCq M3W0ZoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M1LObVI2PzdyNEKz
SACC-83 MY\BdI9xfG:|aYOgRZN{[Xl? NGGxepYzOMLizszNxsA> NUTDNnVEOjUEoHi= M2K3U4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> M2PlZlI2PzdyNEKz
HeLa  NXHHW3ZPTnWwY4Tpc44hSXO|YYm= M4jhb|IxNzRyL{iwJO69VQ>? MXiyOOKhcA>? NITMNZV2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? MXSyOVc4ODR{Mx?=
SACC-83 NFPuPGlHfW6ldHnvckBCe3OjeR?= M3PsVFIxNzRyL{iwJO69VQ>? NWjQc3k1OjUEoHi= M{K0OZVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV M4nRUVI2PzdyNEKz
HLCZ01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;xeFDjiJN4MNMgxtVO Mkm5OFghcA>? MX\EUXNQ NWPXcYxScW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlvVNlU4OjR6OUm=
HLCZ01 MV;GeY5kfGmxbjDBd5NigQ>? M{D4RlQxyqEQvF2= MXSyOEBp MWfEUXNQ Ml;wbY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> MV6yOVczPDh7OR?=
HLCZ01 NH3RSm1CeG:ydH;zbZMhSXO|YYm= MWq0NOKh|ryP NVzEbVRjOjRiaB?= NWjXemJtTE2VTx?= NUTqV3g3\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z MnTtNlU4OjR6OUm=
HLCZ01 MWjGeY5kfGmxbjDBd5NigQ>? M4fre|QxyqEQvF2= MVuyOEBp NH7yTmZFVVOR NUH1UFZtcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y M3HJSVI2PzJ2OEm5
MGC803 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PlUFAuPjBizszN NYPiVHFOPzJiaB?= M4X5W2lEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN NUm4OFZtOjV5MEGzO|g>
SGC7901 NGrPfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jE[FAuPjBizszN NVf3WIk2PzJiaB?= NW\xb29jUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> NHfjbnczPTdyMUO3PC=>
MGC803 MUnGeY5kfGmxbjDBd5NigQ>? NVr0TWtmPDEEoN88US=> MV:4M|E3NzJ2IHi= NYXFT|hkfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NYfFXnFLOjV5MEGzO|g>
SGC7901 NIPp[WtHfW6ldHnvckBCe3OjeR?= M4HEO|QxyqEQvF2= Mk\lPE8yPi9{NDDo NEjTZ2R2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> MlvkNlU4ODF|N{i=
MCF-7  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;2RVEwOTBizszN M2XFfFczKGh? NWfReIs4TE2VTx?= Mo\h[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? M3v1WlI2PjZ5NUGw
MDA-MB-231  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33pdFEwOTBizszN MXG3NkBp M4PGWGROW09? MXPlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? NGTSUIozPTZ4N{WxNC=>
MDA-MB-231 MknUSpVv[3Srb36gRZN{[Xl? NV;HXHlHOC12MDFCuW0> NUXGN2Y4PC1{NDDo M{TROolv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MXOyOVU5PzN{OR?=
MCF-7 MmnLSpVv[3Srb36gRZN{[Xl? MormNE01OCEEtV2= NYDxdXN3PC1{NDDo MXPlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh NHLSOVkzPTV6N{OyPS=>
MCF7-MX  NYTYb2RzTnWwY4Tpc44hSXO|YYm= NYDEZYp5OC12MDFCuW0> MUG0MVI1KGh? MoXC[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NUi0WpRmOjV3OEezNlk>
MDA-MB-231 NW\2VFFrTnWwY4Tpc44hSXO|YYm= MVOwMVQxKML3TR?= NWrqPFRGPC1{NDDo MljZd5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi NX\5Z|dzOjV3OEezNlk>
A2780 NHKzTlJHfW6ldHnvckBCe3OjeR?= MVi1M|ExNzF3IN88US=> NGmw[FA1QCCq MYLk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWCwUXlWOjV2MkS4PVg>
SKOV3  MWHGeY5kfGmxbjDBd5NigQ>? M1\BS|UwOTBxMUWg{txO NI\Ob|M1QCCq NXLTVoFW\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWKyOVQzPDh7OB?=
A2780 NV;U[VFTTnWwY4Tpc44hSXO|YYm= M2ezVlUwOTBxMUWg{txO NVTufVZ3PDhiaB?= M330ZoVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? M4Hs[FI2PDJ2OEm4
SKOV3  MXrGeY5kfGmxbjDBd5NigQ>? NW\hclR{PS9zMD:xOUDPxE1? NEPMWJY1QCCq MmPi[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? MUiyOVQzPDh7OB?=
A2780 NVTleHlVTnWwY4Tpc44hSXO|YYm= MVq1M|ExNzF3IN88US=> M3HWOlQ5KGh? MnXY[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw NFe3bFQzPTR{NEi5PC=>
SKOV3  MYrGeY5kfGmxbjDBd5NigQ>? NHXkNpI2NzFyL{G1JO69VQ>? MWW0PEBp MUfk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? MViyOVQzPDh7OB?=
A2780 NIfFO5NHfW6ldHnvckBCe3OjeR?= MojHOU8yOC9zNTFOwG0> NIi4W20yKGh? MmXDbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUXEbYJXOjV2MkS4PVg>
SKOV3  M2jCVGZ2dmO2aX;uJGF{e2G7 MX[1M|ExNzF3IN88US=> M2LiW|EhcA>? MoXjbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXfWRXduOjV2MkS4PVg>
HCT-15 MmjsSpVv[3Srb36gRZN{[Xl? MnfwNVAuPTBizszN MXS2MVM3KGh? NWDxSY9PcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M4m5VFI2OjF6MEK4
HT-29  NYDqSWkxTnWwY4Tpc44hSXO|YYm= NUHlPYFHOTBvNUCg{txO NHnjWFE3NTN4IHi= NVrVV5RbcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> M372clI2OjF6MEK4
HSC3  NEfiU5hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVPFVY1MOOLCk{SwJO69VQ>? NYjTTFB7PDhiaB?= M37pXWlEPTB;MkWuOeKyOS55OECg{txO M4PSdlI2OTl6N{i5
HSC3  MlHaRZBweHSxc3nzJGF{e2G7 NHK2doszPSEQvF2= NVzPeZAzPDhiaB?= MWrpcoR2[2W|IHHwc5B1d3Orcx?= NYDDbYxEOjVzOUi3PFk>
HSC3  NUDK[VlHTnWwY4Tpc44hSXO|YYm= MmX3NlUh|ryP Mln5OFghcA>? MX\lfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV MVuyOVE6QDd6OR?=
HSC3  NVznOIZiTnWwY4Tpc44hSXO|YYm= M4nKSFI2KM7:TR?= NIX6Tng1QCCq M{PqOIlvcGmkaYTzJGhUSzNiY3XscEBqdn[jc3nvckBkd22kaX7l[EB4cXSqIFPFWC=> NGDONFUzPTF7OEe4PS=>
HSC3  NWq0dWNVTnWwY4Tpc44hSXO|YYm= MkLtNlUh|ryP NXzDR44{PzJiaB?= MVzk[YNz\WG|ZYOgUW1RNTJiYX7kJG1OWC17IIDyc5RmcW6|wrC= M2LiU|I2OTl6N{i5
201T  M1HpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDGO|IhcA>? Mm\uSG1UVw>? MWXJR|UxRTR6Lk[gxtVO MViyOVA2Pzl2MR?=
273T NHLCdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTNSWQ4OiCq MV7EUXNQ M{[zTWlEPTB;OECuOUDDvU1? NXjxTHhROjVyNUe5OFE>
Hep-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3mN|AwPTBxMUCwJO69VQ>? NXroRZNlOTJxMkSvN|YwPDhiaB?= NHzqcHhFVVOR MoLCbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoHoNlQ6QTh3NkS=
Hep-2 NX7ldlFZSXCxcITvd4l{KEG|c3H5 MVu1NEDPxE1? NWqxVnJNOC12ODDo NHzTNpVFVVOR MYfpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NWHafJhPOjR7OUi1OlQ>
Hep-2 NX7uSJZCTnWwY4Tpc44hSXO|YYm= MnXmOVAh|ryP M1zSeVAuPDhiaB?= NY[yfIM2TE2VTx?= M3rN[5Jm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 NXWzRZpMOjR7OUi1OlQ>
Hep-2 MmjBSpVv[3Srb36gRZN{[Xl? NVzJW|NYPTBizszN MnrUNE01QCCq MVPEUXNQ MX7k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCqVFXSWC=> M4rIe|I1QTl6NU[0
SGC-7901 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nVXlExNzVyL{GwNEDPxE1? M2LWTVI1NzR6L{eyJIg> NYDZcFhYTE2VTx?= M1LUe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUmyOFk6Ojl3OB?=
MKN-45 M2jOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;HVIUyOC93MD:xNFAh|ryP M{LqVlI1NzR6L{eyJIg> MkPlSG1UVw>? M{TocIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVvZPYwxOjR7OUK5OVg>
SGC-7901 MmHPSpVv[3Srb36gRZN{[Xl? MofjNVAwPTBxMUCwJO69VQ>? M1vKfVQ5KGh? MU\EUXNQ NWe3SJV[\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NH2xeVIzPDl7Mkm1PC=>
MKN-45 M3[5U2Z2dmO2aX;uJGF{e2G7 NEHqWnQyOC93MD:xNFAh|ryP NV\SR3pMPDhiaB?= MXrEUXNQ M3nZeYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NV7INmNROjR7OUK5OVg>
C666-1 MYTDfZRwfG:6aXPpeJkhSXO|YYm= NGHleHozOC16MDFOwG0> NGrzXo8zPCCq MlPX[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> Ml\DNlQ5PTR6M{i=
CNE-1 M{DENmN6fG:2b4jpZ4l1gSCDc4PhfS=> NVvzW4k5OjBvOECg{txO NHrSW4EzPCCq NGDJfY1l\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh NXyxPGZ[OjR6NUS4N|g>
CNE-2 NELMS5hEgXSxdH;4bYNqfHliQYPzZZk> NIX5VmwzOC16MDFOwG0> MXGyOEBp NUXPc41[\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYP5PG5SOjR6NUS4N|g>
C666-1 Mnm4R5l1d3SxeHnjbZR6KEG|c3H5 NILmOIE3OCEQvF2= Mn;HO{Bl NYf1No46\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NVvhWWRUOjR6NUS4N|g>
CNE-1 MWTDfZRwfG:6aXPpeJkhSXO|YYm= M1fxfFYxKM7:TR?= NVPzWFN7PyCm NH23dXpmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> M2DtWVI1QDV2OEO4
SNU-1041 NF;DUFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD2ZnFyOC12MDFOwG0> MV:0PEBp M1P3NolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ MUWyOFY6OjdyMx?=
SNU-1041 MVPGeY5kfGmxbjDBd5NigQ>? MmTYNlAwOzBizszN M1joSFQhcA>? MlnnbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> NF;xXFgzPDZ7MkewNy=>
SNU-1041 NGL3d5RHfW6ldHnvckBCe3OjeR?= NIrDNIcxNTRyIN88US=> MmrjOEBp M17PN5VxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26| M{\ie|I1Pjl{N{Cz
SGC-7901 M{HVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLSOVAuOTJ3IN88US=> M4\KWVI1NzR6L{eyJIg> NW\6RolYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M4np[lI1Pjd4M{m0
SGC-7901 MkDqRZBweHSxc3nzJGF{e2G7 NWnTeW1EOTByIN88US=> NGfKPHc4OiCq NH\RWVBqdmS3Y3XzJIFxd3C2b4Ppdy=> M3H0[VI1Pjd4M{m0
SGC-7901 M1nJOGZ2dmO2aX;uJGF{e2G7 Mm\6O|UwOTByL{GyOUDPxE1? MnXhNlQwPDhxN{KgbC=> NIK0[GVqdmO{ZXHz[ZMh[2G|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=> MVqyOFY4PjN7NB?=
LMeC  NGLyR|BHfW6ldHnvckBCe3OjeR?= NVXRdFk1OjBxNUCg{txO NYntZmY1PDhiaB?= MVjk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>? M3rOfFI1PjV4N{S2
CMeC-1 MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MorUNlAwPTBizszN M4X0UlQ5KGh? NUWxdXVKcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NHvR[FczPDZ3Nke0Oi=>
LMeC MkTJR4VtdCCYaXHibYxqfHliQYPzZZk> MYmyNE82OCEQvF2= NG[zTXk1QCCq NFW3eHZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1vCdVI1PjV4N{S2
CMeC-1 M4fVVmZ2dmO2aX;uJGF{e2G7 MWOyNE82OCEQvF2= M4XNeVQ5KGh? MX7pcoR2[2W|IFexMXMh[XK{ZYP0 NXHYfGgxOjR4NU[3OFY>
LMeC MXLGeY5kfGmxbjDBd5NigQ>? MWCyNE82OCEQvF2= MnnqOFghcA>? Ml7ObY5lfWOnczDHNU1UKGG{cnXzeC=> NFviO4UzPDZ3Nke0Oi=>
CMeC-1 M1\USmZ2dmO2aX;uJGF{e2G7 MoDUNlAwPTBizszN M3jMPVQ5KGh? NYTqTodF\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4nVZVI1PjV4N{S2
LMeC M3PFNmZ2dmO2aX;uJGF{e2G7 NX21ToJiOjBxNUCg{txO MnHtOFghcA>? MULk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVnjfm45OjR4NU[3OFY>
CMeC-1 NEfOUpVHfW6ldHnvckBCe3OjeR?= MWiyNE82OCEQvF2= NHLvUoM1QCCq MnH6bY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> NGfHOGczPDZ3Nke0Oi=>
LMeC NVL1T4FxTnWwY4Tpc44hSXO|YYm= MkPGNlAwPTBizszN M{mxOFQ5KGh? M2qwOolv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NVj6U3FzOjR4NU[3OFY>
OVCAR-3 NUW2WY9lS2WubDDWbYFjcWyrdImgRZN{[Xl? MWixNEDDvU1? NF3kem8yKGh? M3vkToVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MViyOFUzODJ{Nx?=
OVCAR-3 NUj5UpROSXCxcITvd4l{KEG|c3H5 MUixNEDDvU1? MlLmNUBp NVyzfpJUeHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MlPONlQ2OjB{Mke=
OVCAR-3 MV;GeY5kfGmxbjDBd5NigQ>? NYfIS|ZGOTBiwsXN MVSxJIg> NX\kc2NF\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> MWCyOFUzODJ{Nx?=
OVCAR-3 MUTGeY5kfGmxbjDBd5NigQ>? NFjGfXUyOCEEtV2= M2DCUFEhcA>? M3;acIRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> MknkNlQ2OjB{Mke=
OVCAR-3 NVzCWYY{TnWwY4Tpc44hSXO|YYm= NXztTlFPOTBiwsXN Mm\xNUBp MVHpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MX[yOFUzODJ{Nx?=
CF33 Mm\MSpVv[3Srb36gRZN{[Xl? NVH4VIhyOTByIN88US=> M2jSfVI1KGh? MYLpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? NV;3c4JCOjR3MEO3PFI>
CF33 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGxNE0yODBizszN NGXNTWUxNTRiZB?= MojPbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmjrNlQ2ODN5OEK=
CF33 MWXGeY5kfGmxbjDBd5NigQ>? NWKx[HpZOTBvMUCwJO69VQ>? MX[0MVI1KGh? M{\OOYRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? MYSyOFUxOzd6Mh?=
LNCaP MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfEXVBEOi93L{GwJO69VQ>? M2DHXVk3KGh? MoLXbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= MmPwNlQzQTZ7N{i=
LNCaP MknRRZBweHSxc3nzJGF{e2G7 MlvLNk82NzFyIN88US=> MnzzPVYhcA>? NGL6b25qdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MX2yOFI6Pjl5OB?=
PC-3  NVT4NYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq5[|IxNTVyIN88US=> M3XGVVQ56oDLaB?= MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXOyOFEzPzh6Mh?=
PC-3  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{PJTVAuOTByIN88US=> M3X0T|czKGh? MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MmXvNlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID